BioCentury
ARTICLE | Finance

All-in endocrine

How Millendo transformed itself into endocrine play with $62M B round, AZ deal

January 11, 2016 8:00 AM UTC

New biological insights into Atterocor Inc.'s lone compound combined with asset sleuthing by founding VC Frazier Healthcare have morphed the company into Millendo Therapeutics Inc., an endocrine play with a pair of first-in-class molecules in development for four indications.

To fund the expanded pipeline, the company raised $62 million in a series B round last week led by New Enterprise Associates. Other investors included Roche Venture Fund, Adams Street Partners, Altitude Life Science Ventures, Longwood Fund, Renaissance Venture Capital Fund, Frazier, Osage University Partners, 5AM Ventures and the Regents of the University of Michigan...